Hiring in life sciences? Share your open positions with our professional community. Read more Close

Your cookie settings

This site uses cookies. Some cookies are essential to make the site work and others help us to improve our services. Read more about cookies in our Privacy policy.

Choose your cookie preferences:

Advertisement

Enfortumab vedotin plus pembrolizumab in cisplatin-eligible muscle-invasive bladder cancer: efficacy proven, duration unclear.

Created on 22 Oct 2026

Authors

Massimiliano Depalma, Francesco Rossi, Matteo Ferro, Laura Bukavina, Giuseppe Di Lorenzo, Riccardo Autorino

Published in

BJU international. Oct 21, 2026. Epub Oct 21, 2026.

PMID:
42902827
Bibliographic data and abstract were imported from PubMed on 22 Oct 2026.

Read full publication at:
Please sign in to see all details.

Advertisement

Stats

  • Community rating n/a 0 votes
  • Reviewers' rating n/a 0 votes
  • Sign in to post a review. Add review
  • Your rating

1-terrible, 9-excellent. How would you rate this publication? Sign in in to submit your rating.

  • Recommendations n/a n/a positive of 0 vote(s)
  • Views 16
  • Comments 0

Recommended by

  • No recommendations yet.

Do you recommend this? Please sign in. Yes No

Recommended

Post a comment

You need to be signed in to post comments. You can sign in here.

Comments

There are no comments yet.

Advertisement